Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030
Steffan98705 Jul, 2021Health
Over 170 product candidates are currently under various stages of development for a diverse range of back of the eye disorders. 8 drugs are commercially available; of these, Lucentis? and Eylea? have already achieved blockbuster status. Nearly 40% of the pipeline molecules are under clinical development; specifically, 1 product candidates are in the pre-registration stage
Related Bookmarks
- Effective Remedies to Cure Scleroderma Naturally
- Cancer Stem Cell Therapies Market, 2017-2030
- Glycated Albumin Assay is the First-ever Test to Measure and Evaluate the Total Glycated Albumin Pre
- Demand for Geriatric Care Services Has Increased Due to Growing Geriatric Population
- Gastroscopy devices has become essential in the diagnosis of mucosal disorders of the gastrointestin
- Eldershield Assessment
- Gamma Knife Surgery Process Is a Kind of Radiation Therapy, Which Is Used To Various Abnormalities i
- Wie k�nnen Sie die Probleme der erektilen Dysfunktion und des Gewichtsverlusts heilen?
- CBD extracts-Benefits of making skin glow
- Top Differences between Naturopathy and Homeopathy
Recent Profiles
Stardeck Group
32wincapital1
Lode247top
Onbet
Lisa Bestic
Miles Wooten
Kjeldgaard Joyner
Barefoot Kenney
Flanagan Munksgaard
Lindsey Caspersen